MDACC Study No:2013-0425 ( NCT No: NCT01855750)
Title:A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:Cyclophosphamide; Doxorubicin; Ibrutinib; Prednisone; Rituximab; Vincristine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if giving Imbruvica
(ibrutinib) with the combination of rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone (also known as R-CHOP) can help to control DLBCL,
compared to treatment with R-CHOP alone. The safety of this combination will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase III
Treatment Agents:Cyclophosphamide
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Janssen Research & Development, LLC
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults